{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:10:02Z","timestamp":1790237402376,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-003"],"award-info":[{"award-number":["2021-I2M-1-003"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-A-003"],"award-info":[{"award-number":["T-A-003"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-MSDZD2021-0213"],"award-info":[{"award-number":["Y-MSDZD2021-0213"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L248022"],"award-info":[{"award-number":["L248022"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z221100007922039"],"award-info":[{"award-number":["Z221100007922039"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018538","name":"National Ten Thousand Talent Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xcrm.2025.102349","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:26:08Z","timestamp":1758619568000},"page":"102349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Xueshuai","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianing","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102349_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12254-021-00703-7","article-title":"CAR T cell therapy in solid tumours: a short review","volume":"14","author":"Umut","year":"2021","journal-title":"Memo"},{"key":"10.1016\/j.xcrm.2025.102349_bib2","article-title":"Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity","volume":"5","author":"Tan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102349_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/gm505","article-title":"Intra-tumour heterogeneity: lessons from microbial evolution and clinical implications","volume":"5","author":"Bruin","year":"2013","journal-title":"Genome Med."},{"key":"10.1016\/j.xcrm.2025.102349_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102349_bib5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102349_bib6","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL Therapy: Facts and Hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102349_bib7","first-page":"5263","article-title":"Clonal analysis of lymphocytes from tumour, peripheral blood, and nontumourous kidney in primary renal cell carcinoma","volume":"50","author":"Kim","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102349_bib8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumour antigen-specific CD8 T cells infiltrating the tumour express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102349_bib9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8(+) tumour-reactive repertoire infiltrating human tumours","volume":"124","author":"Gros","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102349_bib10","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102349_bib11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2020.09.048","article-title":"Detecting Tumour Antigen-Specific T Cells via Interaction-Dependent Fucosyl- Biotinylation","volume":"183","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102349_bib12","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1158\/0008-5472.CAN-20-2300","article-title":"T Cells Expanded from PD-1(+) Peripheral Blood Lymphocytes Share More Clones with Paired Tumour-Infiltrating Lymphocytes","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102349_bib13","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumours by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102349_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102349_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumour efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102349_bib16","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumour-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102349_bib17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102349_bib18","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102349_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.858021","article-title":"Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed\/Refractory CD30+ Lymphoma","volume":"13","author":"Sang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102349_bib20","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B- cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102349_bib21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A Chimeric Switch-Receptor Targeting PD-1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumours","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102349_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T Cells that Express a PD-1\/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102349_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4939-8979-9_7","article-title":"Expansion of Tumour-Infiltrating Lymphocytes from Melanoma Tumours","volume":"1913","author":"Wickstr\u00f6m","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102349_bib24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:14:07Z","timestamp":1788563647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125004227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666379125004227"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102349","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102349"}}